Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Fleming v. Impax Laboratories Inc. et al
Case Number:
4:16-cv-06557
See also:
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 15, 2022
Impax Investor Attys Score $9.9M Fees In Price-Fixing Suit
A California federal judge on Friday granted $9.9 million in attorney fees and gave final approval to a $33 million settlement that resolves claims that generic-drug maker Impax Laboratories Inc. failed to disclose a federal investigation over possibly collusive market activity.
-
August 02, 2021
Impax Inks $33M Deal With Investors In Price-Fixing Suit
A proposed class of Impax Laboratories Inc. investors asked a California federal judge to preliminarily approve a $33 million settlement that would resolve claims the generic-drug maker failed to disclose a federal investigation over possibly collusive market activity.
-
August 12, 2019
Investors' Impax Drug Price-Fixing Suit Fails Again
A California federal judge on Monday again dismissed a shareholder suit alleging generic-drug maker Impax Laboratories Inc. failed to disclose to investors a federal investigation over possibly collusive market activity, finding the shareholders failed to remedy the issues that got their complaint tossed the first time around.
-
December 07, 2018
Impax Says Investors' Drug Price-Fixing Suit Still Fails
Impax Laboratories has asked a California federal judge to again quash investors' attempt to revive claims that the generic-drug manufacturer hid news of a federal investigation into whether it was colluding with its competitors to fix the prices of two generic drugs, saying the latest complaint still misses the mark.
-
September 07, 2018
Impax Escapes Investors' Drug Price-Fixing Suit, For Now
A California federal judge on Friday dismissed a shareholder suit alleging generic-drug maker Impax Laboratories Inc. failed to disclose to investors a federal investigation over possibly collusive market activity, but also threw investors a life jacket, saying it's possible they could allege a scheme if they can elaborate how executives allegedly fixed prices.